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Introduction
Daduang et al. in this issue of Archives of Medical Science evaluate a dis-
integrin and metalloprotease (ADAM)12 level as a distinguishing biomarker
between hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC) [1].
Mean serum levels of ADAM12 in their study were higher in HCC compared
with both CC and healthy controls (p < 0.001 for both combinations).
Regarding specificity and positive likelihood ratio (PLR), ADAM12 had bet-
ter specificity and PLR for HCC compared with CC (specificity: 77.4% vs.
64.5%, respectively; PLR: 3.51 vs. 1.25, respectively). Furthermore, serum
levels of ADAM12 in HCC correlated with the overall survival (p = 0.02),
indicating that high serum level of ADAM12 are associated with a signifi-
cantly poorer prognosis. The conclusion reached was that ADAM12 may
be used as an adjunct biomarker for the differential diagnosis between
HCC and CC.
Some additional comments may be of interest.
Differential diagnosis between hepatocellular carcinoma
and cholangiocarcinoma: where are we now?
Cholangiocarcinoma accounts for about 3% of all gastrointestinal tumors
and about 15% of all primary liver cancers worldwide [2]. The lack of ear-
ly detection and the limited therapeutic options available are major prob-
lems in the management of CC [2]. Whether intrahepatic immune cells
play a role in the pathogenesis or treatment of hepatic cancers [3] is also
another topic requiring further investigation.
The differential diagnosis between HCC and CC is not easily established
[4, 5]. There are many diversities and pitfalls in the role of genetic factors
in the development of HCC [5], but not CC. Cholangiocarcinoma is more
common in females and in more elderly patients compared with HCC. Fur-
thermore, CC has a lower proportion of asymptomatic tumors, lower serum
α-fetoprotein, higher serum carcinoembryonic antigen, carbohydrate anti-
gen (CA) 19-9 and alkaline phosphatase levels compared with HCC. In CC,
there is also a lower incidence of hepatitis history, associated cirrhosis
and serum hepatitis B surface antigen, a lower proportion of small/well-
encapsulated tumors and tumor emboli in the portal vein, a higher pro-
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portion  of  single  tumor,  perihilar  lymph  node
involvement and poor differentiation and less fre-
quency of limited resection compared with HCC (for
all associations p < 0.0001) [4, 5]. 
Although CA19-9 is the most available marker for
the detection of pancreatic cancers, CC and other
pancreatic malignancies, it may not be an adequate
marker for the differential diagnosis between the 
2 types of tumor [6]. The reason for this is that the
sensitivity and specificity of CA19-9 is often subop-
timal in clinical practice [6]. Furthermore, many
patients with elevated CA 19-9 levels do not have CC,
but instead more benign conditions such as primary
sclerosing cholangiitis [7]. 
A variety of other markers have been proposed
to have a diagnostic or prognostic value for the 2
tumor types. such as αvβ6 integrin [8]. NAD(P)
H:quinone oxidoreductase-1 (NQO1) [9], MUC1 [10]
and thyroid transcription factor (TTF)-1 [11]. The
αvβ6 integrin is strongly expressed in human CC,
but not in HCC and can therefore be considered as
a specific immunohistochemical marker in the dif-
ferential diagnosis of primary liver tumors [8].
A considerable drawback of all the above-men-
tioned markers [8-11] is that they are tissue (not
blood) marker.
A study from China analyzed 5 different serum
tumor markers (α-fetoprotein, carcinoembryonic
antigen, CA19-9, CA242 and CA50) for their ability
to establish the differential diagnosis between CC
and HCC [12]. Serum levels and the positive rate of
α-fetoprotein, CA19-9 and CA242 were different
between the CC and HCC. Additionally, the combi-
nation of AFP (–) and CA242 (+) afforded a high
specificity of 94.3% and the highest accuracy (that
is 78.5%) [12].
In their small study (n = 21 patients), Sriwan-
itchrak et al. attempted to identify novel serum
markers  which  can  substitute  CA19-9,  or  can
improve the diagnostic accuracy of CA19-9 when
measured together with this marker [2]. Based on
the results of binary logistic regression analysis of
3 serum biomarkers (CA19-9, antitrypsin-1 and 
α-fetoprotein), serum levels of CA19-9 together with
antitrypsin-1 were the minimum requirement to
obtain prediction accuracy of greater than 80% 
in a battery test for diagnosis of CCA. However, 
in order to obtain high predictability, an addition of
at least 1 of the 3 liver function enzymes (alkaline
phosphatase, aspartase transaminase or alanine
trasaminase) was required. The conclusion reached
was that serum biomarkers may be a useful diag-
nostic or prognostic monitoring tool for CC, but fur-
ther evaluation in larger trials is required [2].
The lack of a single reliable predictor for the
detection and diagnosis of hepatic tumors has lead
to the development of the so-called Fudan score
[13]. The Fudan score is a combination of various
independent predictors, namely serum alkaline
phosphatase level, CA 19-9 level, tumor boundary
type,  tumor  size  and  number  of  intrahepatic
tumors. A Fudan score may provide a relatively
accurate prognostic prediction of CC regardless of
resection status [13].
As mentioned by Daduang et al. [1], serum lev-
els of ADAM12 in HCC are inversely associated with
the overall survival (p = 0.02), indicating that high
serum level of ADAM12 are associated with a sig-
nificantly poorer prognosis. Future studies should
evaluate whether the addition of ADAM12 in the
above  mentioned  parameters  comprising  the
Fudan score could provide additional predictive val-
ue in the detection and long-term prognosis of
these 2 types of tumor. Furthermore, future stud-
ies should evaluate whether serum biomarkers
may be a useful diagnostic or prognostic monitor-
ing tool for CC.
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